GlaxoSmithKline Sells Meningitis Vaccines to Pfizer For EUR115 Million
22 June 2015 - 9:47PM
Dow Jones News
LONDON-- GlaxoSmithKline PLC (GSK.LN) said Monday it is selling
its meningitis vaccines Nimenrix and Mencevax to Pfizer Inc's (PFE)
Irish subsidiary for 115 million euros ($130.6 million).
Glaxo said it is selling the vaccines to gain regulatory
approval for a deal with Novartis AG (NVS) that includes Glaxo
buying Novartis's vaccines business.
Nimenrix and Mencevax, which are sold outside the U.S. and
achieved combined global sales in 2014 of 34 million pounds ($54
million), Glaxo said.
Shares at 1115 GMT, up 16 pence, or 1.2%, at 1,374 pence valuing
the company at GBP66.8 billion.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2024 to May 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From May 2023 to May 2024